Paxlovid, Drug Exposure
| dc.contributor.advisor | Bailey, Charles |
| dc.contributor.advisor | Brill, Seuli |
| dc.contributor.author | Hirabayashi, Kathryn |
| dc.contributor.other | Children's Hospital of Philadelphia |
| dc.date.accessioned | 2024-06-10T19:03:16Z |
| dc.date.available | 2024-06-10T19:03:16Z |
| dc.date.created | 2022-10-10 |
| dc.description | This concept set was used to identify pediatric patients under 18 who were prescribed Paxlovid. The concept set was developed by identifying RxNorm codes at the SCDF/SCDG level and descendants indicating Paxlovid, then string searching for the terms 'paxlovid', 'ritonavir', and 'nirmatrelvir' in ‘concept_name’. Codes were identified in the ‘code_type’ column as 'Paxlovid' (indicating nirmatrelvir/ritonavir), 'nirmatrelvir' (indicating nirmatrelvir alone) and 'ritonavir' (indicating ritonavir alone). Please note, this concept set should not be used without appropriate accompanying logic to identify Paxlovid; the concept set contains individual ingredients that comprise the combination. Ritonavir and nirmatrelvir exposure must occur together on the same date to indicate a combination drug prescription. The attached file, FIND_PAXLOVID_FUNCITON.R, provides logic showing how the concept set can be used. |
| dc.description.abstract | The concept set was intended to identify all patients with a drug_exposure record indicating a Paxlovid exposure (nirmatrelvir/ritonavir). |
| dc.identifier.uri | https://hdl.handle.net/20.500.14642/458 |
| dc.identifier.uri | https://doi.org/10.24373/pdsp-320 |
| dc.provenance | Initially developed for a "Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study" Y1, Q3 query. The concepts were later reviewed and refined for a brief report on pediatric nirmatrelvir and ritonavir prescribing patterns, "Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic" (Bose-Brill et. al., 2022). |
| dc.publisher | PEDSnet |
| dc.relation.isreferencedby | Bose-Brill S, Hirabayashi K, Pajor NM, Rao S, Mejias A, Jhaveri R, Forrest CB, et al. 2022. "Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic". _medRxiv_ [Preprint]. 2022 Dec 26:2022.12.23.22283868. <br>DOI: [10.1101/2022.12.23.22283868](https://doi.org/10.1101/2022.12.23.22283868) <br>Update in: Hosp Pediatr. 2024 Aug 1;14(8):e341-e348. <br>DOI: [10.1542/hpeds.2023-007132](https://pubmed.ncbi.nlm.nih.gov/36597537) |
| dc.relation.uri | https://atlassian.chop.edu/bitbucket/projects/COV/repos/paxlovid_brief/browse |
| dc.rights | a CC-BY Attribution 4.0 License. |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
| dc.subject.mesh | Ritonavir |
| dc.subject.mesh | Protease Inhibitor |
| dc.subject.mesh | Cytochrome P450 3A Inhibitor |
| dc.subject.mesh | Antimicrobial |
| dc.subject.mesh | Enzyme Inhibitor |
| dc.subject.other | NDC |
| dc.subject.other | RxNorm |
| dc.subject.other | RxNorm Extension |
| dc.title | Paxlovid, Drug Exposure |
| dspace.entity.type | ConceptSet |
| local.quality.status | Needs Refinement |
| local.subject.DataModel | PEDSnet Data Model |
| local.subject.EvalType | Clinician Reviewed |
| local.subject.MedTermChar | Semantic Clinical Drug Form |
| local.subject.MedTermChar | Brand Pack Name |
| local.subject.MedTermChar | Ingredient |
| local.variable.name | rx_paxlovid |
| relation.isStudyOfConceptSet | 4932bc8c-1f72-44ad-aeeb-b7922e38fad3 |
| relation.isStudyOfConceptSet | df5d1a67-2955-4af0-8542-eac194466ad4 |
| relation.isStudyOfConceptSet.latestForDiscovery | 4932bc8c-1f72-44ad-aeeb-b7922e38fad3 |